Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Non-Current Deffered Revenue (2018 - 2025)

Health Catalyst (HCAT) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $385000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue rose 49.22% year-over-year to $385000.0, compared with a TTM value of $385000.0 through Sep 2025, up 49.22%, and an annual FY2024 reading of $249000.0, up 223.38% over the prior year.
  • Non-Current Deffered Revenue was $385000.0 for Q3 2025 at Health Catalyst, up from $329000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.1 million in Q1 2021 and bottomed at $51000.0 in Q2 2024.
  • Average Non-Current Deffered Revenue over 5 years is $427631.6, with a median of $315000.0 recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue crashed 88.7% in 2022, then soared 545.1% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $929000.0 in 2021, then plummeted by 88.7% to $105000.0 in 2022, then decreased by 26.67% to $77000.0 in 2023, then skyrocketed by 223.38% to $249000.0 in 2024, then surged by 54.62% to $385000.0 in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for HCAT at $385000.0 in Q3 2025, $329000.0 in Q2 2025, and $407000.0 in Q1 2025.